Sanofi buys Vigil Neuroscience for $470m in Alzheimer’s push
Sanofi has agreed to acquire Vigil Neuroscience in a $470m deal, nearly a year after investing an initial $40m in…
22 May 2025
Paratek expands commercial portfolio with Optinose
Paratek Pharmaceuticals has completed the acquisition of Optinose, valued at almost $330m, broadening its commercial product offerings. The companies signed a definitive merger agreement in March 2025. The portfolio of…
22 May 2025
Wegovy and Zepbound costs capped at $200 in new Evernorth programme
Evernorth, the pharmacy benefits unit for health insurer giant Cigna, has reached a deal with drugmakers Novo Nordisk and Eli Lilly to cap the out-of-pocket cost for the companies’ popular…
22 May 2025
Lilly’s Kisunla marketing for Alzheimer’s authorised in Australia
Eli Lilly and Company has received marketing authorisation from the Australian Therapeutic Goods Administration (TGA) for Kisunla (donanemab) to treat mild cognitive impairment and mild dementia due to Alzheimer's disease…
22 May 2025
Orionis and Genentech link on oncology small-molecule glue medicines
Orionis Biosciences has announced a multi-year partnership with Roche’s Genentech, focusing on the discovery and development of small-molecule monovalent glue medicines for difficult targets in oncology. This is the second…
21 May 2025
Moderna shares down after pulling Covid-flu combo vaccine application
Moderna has “voluntarily” withdrawn its application to the US Food and Drug Administration (FDA) for approval of its Covid-19 and flu combination vaccine amid a recent tightening of regulatory requirements…
21 May 2025
Viz.ai, Sanofi and Regeneron to link for COPD management
Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered workflow solution for improving the management of chronic obstructive pulmonary disease (COPD).…